SOM Biotech signs licensing agreement with the University of Minnesota

SOM Biotech signs licensing agreement

SOM Biotech announced that it has signed a licensing agreement with the University of Minnesota. This license agreement follows the completion of research under a sponsored research agreement (SRA) signed in 2019, in which the University of Minnesota conducted a series of in vitro studies on potential pre-clinical product candidates for Duchenne and Becker muscular …

SOM Biotech signs letter of intent with Megapharm to commercialize SOM3355 in Israel and the Palestinian Authority

SOM Biotech (“SOM” or the “Company”), a clinical-stage biopharmaceutical company with a proprietary AI-based drug discovery technology and a focus on neurological orphan diseases, today announces that it has signed a letter of intent with Megapharm Ltd. (“Megapharm”), a leading Israel-based pharmaceutical company, regarding a potential exclusive distribution agreement for the commercialization of SOM3355 to …

SOM Biotech granted Orphan Drug Designation by the FDA for SOM3355

~SOM3355 has the potential to be an alternative to current VMAT2 inhibitors with a significantly improved side effect profile for the treatment of chorea in Huntington´s disease~  SOM Biotech (“SOM” or the “Company”), a clinical-stage drug discovery and development company focused on orphan diseases of the Central Nervous System, today announces that the U.S. Food …

SOM Biotech presents positive Phase 2a data with SOM3355 at the 34thECNP Congress 2021

SOM Biotech presents positive Phase 2a data with SOM3355

~Data show SOM3355 reduces chorea in patients with Huntingdon’s Disease and has a good safety profile~ ~SOM3355 discovered through SOM Biotech’s proprietary artificial intelligence-based computational technology SOMAI PRO~ SOM Biotech today announces it will be presenting positive Phase 2a data with SOM3355, an oral vesicular monoamine transporter 2 (VMAT2) inhibitor for the symptomatic treatment of …